TrialPanorama/TrialPanorama-database huggingface dataset:
Primary endpoint: Acceptance of the interventions
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Haemostatic efficacy
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Incremental Recovery of VWF
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Incremental Recovery of FVIII
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Oppositional Defiant Disorder (ODD) Score
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Mean Change in Pain
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Echocardiographic markers of diastolic dysfunction
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Infection-associated adverse events rate
Endpoint domain: Adverse events/effects
Primary endpoint: Proportion of subjects improving >/= 15 letters of best-corrected distance visual acuity
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Distribution of visual acuity changes at 18 weeks
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Percentage of Participants Reporting at Least 1 Solicited Local and Systemic Adverse Events (AEs)
Endpoint domain: Adverse events/effects
Primary endpoint: Symptoms of pelvic floor prolapse
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in Shortness of Breath Questionnaire score
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Incidence of Inhibitory Antibodies Against FIX
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Change in cognition (ADAS-Cog)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Change in cognition (MMSE)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Proportion of Participants With >/= 2-Step Improvement in DRSS
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Levels of coagulation pathway markers
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Number of needle repositioning to reach the target
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: transcutaneous PCO2
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: transcutaneous PO2
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Number of occurrence sites of acute GVHD
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Severity of acute GVHD
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Number of occurrence sites of chronic GVHD
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Classification of chronic GVHD
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Safety as assessed by laboratory assessments
Endpoint domain: Adverse events/effects
Primary endpoint: Management of obstetric complications
Endpoint domain: Physiological/clinical
Endpoint subdomain: Pregnancy and childbirth outcomes
Primary endpoint: Management of perinatal complications
Endpoint domain: Physiological/clinical
Endpoint subdomain: Pregnancy and childbirth outcomes
Primary endpoint: Peak Plasma Concentration (CMAX) of isotretinoin
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Area under the plasma concentration versus time curve (AUC) of isotretinoin
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: 2-FA PET scan results
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Mortality during follow up
Endpoint domain: Mortality/survival
Primary endpoint: Seven-day Point Prevalence Abstinence
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Percentage of patients with treatment related adverse effect
Endpoint domain: Adverse events/effects
Primary endpoint: number of surgical site infections
Endpoint domain: Adverse events/effects
Primary endpoint: Hopkins Verbal Learning Test
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cognitive functioning
Primary endpoint: Intraoperative analgesics requirement
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Functional status on activities of daily living
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Functional decline in activities of daily living
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: reported side effects
Endpoint domain: Adverse events/effects
Primary endpoint: surgery procedure
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Distant recurrence-free interval
Endpoint domain: Mortality/survival
Primary endpoint: Number of Participants With Cycle 1 Dose-limiting Toxicities (DLT)
Endpoint domain: Adverse events/effects
Primary endpoint: Presence of biofilm in chronic wounds
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Composition of granulosa cells and oocytes
Endpoint domain: Physiological/clinical
Endpoint subdomain: Reproductive system and breast outcomes
Primary endpoint: Percentage of patients with HIV-1 RNA levels < 50 copies/mL
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Percent O-GlcNAcase Enzyme Occupancy
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Success rate of endotracheal intubation procedure
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Intubation skill performance
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Left ventricular pressure and volume
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Change in Average Daily Spasm Count
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Annualized Rate of Change in Tau Burden
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Physical function at 12 months
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: percent change in plasma sitosterol concentration
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Tobacco screening
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Tobacco cessation advice
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Sustained Viral Response (SVR) at 24 Weeks Off Treatment
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Percentage of Participants With Adverse Events and AEs of Special Interest
Endpoint domain: Adverse events/effects
Primary endpoint: Percentage of Participants With Marked Laboratory Abnormalities Based on Hematology, Blood Chemistry, Coagulation and Urinalysis Test Results
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Percentage of Participants With Electrocardiogram (ECG) Abnormalities
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Cardiac Death or Myocardial Infarction Rate
Endpoint domain: Mortality/survival
Primary endpoint: Number of participants with clinically significant changes in ECG
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Complete remission (CR + CRi) achievement
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Fat attenuation index
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: 12-month success rate (IOP reduction)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Ocular outcomes
Primary endpoint: Repeat 12-month success rate (IOP reduction)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Ocular outcomes
Primary endpoint: Generalizability of IOP-lowering efficacy
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Predictive Tumor Cell Biomarkers
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: antioxidant enzymes levels (SOD, GSH-Px, Catalase)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: lipid peroxidation marker (MDA, urinary 8 epi-PGF 2alpha)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: number of patients who proceed to transplant
Endpoint domain: Mortality/survival
Primary endpoint: Postoperative recall of auditory stimuli
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: Postoperative recall of visual stimuli
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: MISSION Fidelity Index
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Serum tocopherol levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Ocular surface healing
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Implementation of clinical intervention
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Length of inpatient HF hospitalisation
Endpoint domain: Resource use
Endpoint subdomain: Hospital
Primary endpoint: Time to clinical stability (days)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Immunogenicity of recombinant HIV-1 Clade A env rAd35 vaccine
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Immunogenicity of recombinant HIV-1 Clade A env rAd5 vaccine
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Surgeon's Ability to Achieve a Staple Line at the Desired Level of the Rectum
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Ability to Achieve Adequate Distal Margins in the Low Rectum
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: acne lesions
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: Primary end points
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Percentage of Subjects With Primary Patency of the Target Lesion at One Year
Endpoint domain: Physiological/clinical
Endpoint subdomain: Vascular outcomes
Primary endpoint: Percentage of Subjects With Composite of Freedom From All-cause Peri-operative Death and Freedom From Index Limb Amputation, Index Limb Re-intervention, and Index-limb-related Death
Endpoint domain: Adverse events/effects
Primary endpoint: Number of Participants With Any Solicited Influenza Symptoms From Day 1 Through Day 10
Endpoint domain: Adverse events/effects
Primary endpoint: Number of Participants With Any Solicited Influenza Symptoms From Day 10 Through Day 13
Endpoint domain: Adverse events/effects
Primary endpoint: Number of Participants With Treatment Emergent Adverse Events of Special Interest (TEAESIs)
Endpoint domain: Adverse events/effects
Primary endpoint: Summary Score of eight ASCOT Domain Scores
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Safety of UC-MSC
Endpoint domain: Adverse events/effects
Primary endpoint: Heat Pain Tolerance Threshold in the area of UVB-induced erythema
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: Number of myocardial infarction and ischaemic stroke
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Number of death due to myocardial infarction or due to ischaemic stroke
Endpoint domain: Mortality/survival
Primary endpoint: Number of severe gastrointestinal (GI) bleeding requiring hospitalization
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Number of intracranial hemorrhage (ICH)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Number of Participants With Severe Graft vs. Host Disease (GVHD)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Dermal-irritation scores
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: Changes in routine clinical laboratory tests and vital signs
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Annual change in FEV1
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Change from baseline VAS
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: stress-induced changes in baroreflex sensitivity
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: blood concentrations of thyroid hormones
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: Trunk Extensor Muscle Cross Sectional Area % of Change
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Patient Reported Postoperative Pain
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Participants Reaching ACR 20 Response
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: absence of postoperative pain
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in global ultrasound scoring system (GLOSS) at MCP and wrist joints
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Dyspnea related distress
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Modified Change in Sequential Organ Failure Assessment (mSOFA) Score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Thrombomodulin Protein
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: GERD-related hospitalization
Endpoint domain: Resource use
Endpoint subdomain: Hospital
Primary endpoint: GERD-related ED visits
Endpoint domain: Resource use
Endpoint subdomain: Hospital
Primary endpoint: Negative Symptoms Assessment
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Child cooperation
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Objective Response as Assessed by the Independent Review Facility (IRF)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Mean Serum Concentration of Dulanermin
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Apparition of Lines B at Lung Ultrasonography
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Pelvic floor muscle strength assessed by palpation
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Pelvic floor muscle strength assessed by ultrasound
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Symptoms of pelvic floor disorders
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Knee coronal plane alignment
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Allergic sensitization at 1 year
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Reduction of LDL-Cholesterol levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Complete or partial remission off treatment
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in Lung Ultrasound Score
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Time to healing of punch biopsy scars
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: Time to healing of the foot ulcers
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: Observed harms and unexpected effects
Endpoint domain: Adverse events/effects
Primary endpoint: semen parameters
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Maximum isokinetic leg extensor strength
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Incidence of Adverse Events Leading to Permanent Discontinuation From Any Study Drug
Endpoint domain: Adverse events/effects
Primary endpoint: Medical Outcomes Survey Short Form (SF12) Mental Component Subscale (MCS) Score
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Zarit Burden Interview (ZBI)
Endpoint domain: Resource use
Endpoint subdomain: Societal/carer burden
Primary endpoint: Proportions of patients receiving appropriate TB treatment
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Overall Pain Intensity
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Severe alteration of quality of life
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Percentage of Participants With Ocular and Non-ocular Adverse Events
Endpoint domain: Adverse events/effects
Primary endpoint: Serum adipocytokines levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Change in flow-mediated vasodilation
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Change in Frequency of Positive Reactions per Allergen
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Infarct size quantitation
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Carotid intima-media thickness (CIMT)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Myocardial stiffness indexes
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Urinary albumin to creatinine ratio excretion
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: Efficacy (Disease Response Rate)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Percentage of Participants With Steady State Drug Concentration Ctrough >20 µg/mL
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Fibroscan reading
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Anatomic recurrence of urethral stricture
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Prevalence of stone disease
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Time to achieve reduction of parasitaemia by 90% of baseline
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Blood Glucose Metabolism
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Staff satisfaction
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Six-month major molecular response rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Clinical activity scores of IBD
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Prevalence of myalgia
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Percentage of Participants With HIV-1 RNA <50 Copies/mL at Week 24
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Percentage of Participants With HIV-1 RNA <50 Copies/mL at Week 48
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of Participants Experiencing Adverse Events (AEs) up to Week 144
Endpoint domain: Adverse events/effects
Primary endpoint: Number of Participants Discontinuing Study Drug Due to AEs up to Week 144
Endpoint domain: Adverse events/effects
Primary endpoint: Maximum tolerated dose (MTD) of ASN001
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Incidence and severity of hypoglycemia
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Liver laboratory tests
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Incidence, type, and severity of islet transplant-related infectious complications
Endpoint domain: Adverse events/effects
Primary endpoint: Proportion of recipients developing alloantibodies
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Incidence, timing, and severity of adverse events
Endpoint domain: Adverse events/effects
Primary endpoint: Adherence to mammography and Pap test screening guidelines
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: impact on functionality
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Protein-specific antigen (PSA) levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of Urge Urinary Incontinence (UUI) Episodes
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: Number of subjects with bronchoconstriction
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Percent calories from fat
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Fruits and Vegetables consumption
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: PASAT
Endpoint domain: Cognitive functioning
Primary endpoint: Trail making test A+B
Endpoint domain: Cognitive functioning
Primary endpoint: Subject's General Satisfaction With Test Catheter
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life